Helen of Troy Ltd header image

Helen of Troy Ltd

HELE

Equity

ISIN BMG4388N1065 / Valor 938381

NASDAQ (2024-11-20)
USD 66.80-0.43%

Helen of Troy Ltd
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

Helen of Troy Ltd is a multinational consumer products company with a diversified portfolio of well-known brands, generating $2.1 billion in sales in fiscal 2023. The company has a proven track record of growth through both organic means and strategic acquisitions, with a focus on expanding operating margins and improving efficiency. Helen of Troy operates in two main business segments: Beauty & Wellness and Home & Outdoor, with a strong emphasis on new product innovation, quality, and competitive pricing. The company's global presence and commitment to building strong partnerships with suppliers have contributed to its leading market positions and continued success in the industry.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (14.08.2024):

Net Sales Decline

Helen of Troy Ltd reported a consolidated net sales revenue of $416.8 million for the first quarter of fiscal 2025, marking a 12.2% decrease compared to the same period in fiscal 2024. This decline was primarily driven by reduced sales in hair appliances, prestige hair care products, and humidifiers within the Beauty & Wellness segment, as well as lower replenishment orders from retail customers in the Home & Outdoor segment.

Gross Profit Margin Expansion

Despite the decline in net sales, Helen of Troy Ltd achieved a gross profit margin of 48.7% in the first quarter of fiscal 2025, an improvement of 330 basis points from 45.4% in the same quarter of the previous year. This increase was attributed to a favorable segment mix, lower commodity and product costs, and reduced inventory obsolescence expenses.

Operating Income and Margins

Helen of Troy Ltd's operating income for the first quarter of fiscal 2025 was $30.8 million, or 7.4% of net sales revenue, compared to $40.6 million, or 8.6% of net sales revenue, in the same period of fiscal 2024. The decrease in operating margin was primarily due to higher selling, general, and administrative expenses, partially offset by the gross profit margin expansion.

Adjusted Earnings Per Share

For the first quarter of fiscal 2025, Helen of Troy Ltd reported a GAAP diluted EPS of $0.26, down from $0.94 in the same quarter of the previous year. On a non-GAAP adjusted basis, diluted EPS was $0.99, compared to $1.94 in the first quarter of fiscal 2024. The decrease in adjusted EPS was mainly due to lower adjusted operating income and a higher effective income tax rate.

Updated Fiscal 2025 Outlook

Helen of Troy Ltd has updated its fiscal 2025 outlook, lowering its consolidated net sales forecast to a range of $1.885 billion to $1.935 billion. The company also revised its GAAP diluted EPS guidance to $4.69-$5.45 and adjusted diluted EPS to $7.00-$7.50. Additionally, the adjusted EBITDA forecast was lowered to $287-$297 million, and free cash flow is now expected to be between $220 million and $240 million.

Summarized from source with an LLMView Source

Key figures

-36.1%1Y
-73.1%3Y
-56.9%5Y

Performance

52.0%1Y
46.6%3Y
44.7%5Y

Volatility

Market cap

2122 M

Market cap (USD)

Daily traded volume (Shares)

154,307

Daily traded volume (Shares)

1 day high/low

67.5 / 66.155

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Towa Yakuhin KK
Towa Yakuhin KK Towa Yakuhin KK Valor: 248084
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.32%JPY 2,827.00
Verona Pharma PLC
Verona Pharma PLC Verona Pharma PLC Valor: 36485349
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.00%USD 38.85
RadNet Inc
RadNet Inc RadNet Inc Valor: 2812237
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.89%USD 82.16
Opko Health Inc
Opko Health Inc Opko Health Inc Valor: 3094438
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.47%USD 1.58
Legend Biotech Corporation
Legend Biotech Corporation Legend Biotech Corporation Valor: 54834759
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
4.53%USD 40.14
AMEDISYS Inc
AMEDISYS Inc AMEDISYS Inc Valor: 399513
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.00%USD 90.00
Revance Therapeutics Inc
Revance Therapeutics Inc Revance Therapeutics Inc Valor: 23239569
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.06%USD 3.80
Corcept Therapeutics Inc
Corcept Therapeutics Inc Corcept Therapeutics Inc Valor: 1812837
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
3.29%USD 56.09
Revolution Medicines Inc
Revolution Medicines Inc Revolution Medicines Inc Valor: 52143299
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.06%USD 57.07
Strategic Education Inc
Strategic Education Inc Strategic Education Inc Valor: 42985312
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.70%USD 95.52